Novo Nordisk’s semaglutide failed in pivotal Alzheimer’s disease studies. Market reaction was negative, but there are still reasons to invest. Shares down 60% since July 2024 due to clinical setbacks. Semaglutide didn’t show benefit over placebo in phase 3 studies, typical for AD drug development challenges.

Despite the setback, Novo Nordisk has seen progress in other areas. Requested approval for higher dose of Wegovy in the US, showing more weight loss than current version. Phase 2 trial success for anti-obesity therapy amycretin. Await oral Wegovy approval and other next-gen therapies to boost sales.

Novo Nordisk’s financial results have been lackluster, but stock could be a steal. Strong mid- and late-stage pipelines, growing revenue, and dividend yield of 3.5% make shares attractive. AD setback doesn’t change overall prospects. Consider investing in other top stocks recommended by analysts for potential high returns.

Read more at Yahoo Finance: Time to Sell the Stock?